One of the greatest challenges in Parkinson's disease is that diagnosis often occurs after significant neurological changes have already taken place. Researchers now believe the disease may begin years—or even decades—before the motor symptoms that typically trigger clinical evaluation. By the time symptoms appear, most patients have lost 60% to 80% or more of the dopamine-producing cells in the substantia nigra. This growing understanding has intensified the search for reliable biomarkers that could improve diagnosis, monitor disease progression, guide clinical trial recruitment, and support the development of new therapies.

The element helium is often associated with party balloons and novelty uses. However, the shortage of high-grade helium following the commencement of hostilities in the Middle East on February 28, 2026, presents a significant and underappreciated risk for the life sciences sector. The conflict has created a potentially long-lasting impact on the cost and availability of medicinal products and critical inputs such as helium, which is essential for the operation of certain medical devices.

In a recent post on this blog, we examined the U.S. Food and Drug Administration's (FDA) core regulatory framework for artificial intelligence (AI) and machine learning (ML) enabled medical devices — the Predetermined Change Control Plan (PCCP), the clinical decision support boundary question, cybersecurity mandates, and what the framework means for company legal and regulatory teams. This article examines converging obligations that extend beyond that foundation.